RAD51 and ovarian cancer: Deletion of C-terminal region of BRCA2 or mutants like BRCA2 6174delT and 6158insT impair the RAD51- binding activity of this domain, diminish the RAD51 recruitment to the damage site, and thereby increase the risk of tumor incidence in mice and early onset of breast and ovarian cancers in human [104, 105].